Clinical Trial Update: A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

View source ↗

Summary

This is a completed real-world study of ribociclib used as first-line therapy for metastatic hormone receptor-positive, HER2-negative breast cancer. It reports …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic HR+/HER2- Breast Cancer | Status: COMPLETED